Mcl-1 expression, however, does not seem to be the unique factor determining the susceptibility towards CG treatment as the comparison between basal levels of the major anti-apoptotic Bcl-2 family proteins (Figure 1c) and susceptibility to UNBS1450 in the panel of cancer cell lines examined (Table 1) is suggesting. The gene discussed is MCL1; the disease is cancer.